

NOTICE OF CHANGE IN CORPORATE STRUCTURE

National Instrument 51-102 - Section 4.9

Item 1: Names of the Parties to the Transaction

Kidani Capital Partners Inc. (“**Kidani**”)
804-750 West Pender Street
Vancouver, BC V6C 2T7

1040426 B.C. Ltd. (“**1040426**”)
804-750 West Pender Street
Vancouver, BC V6C 2T7

1040428 B.C. Ltd. (“**1040428**”)
804-750 West Pender Street
Vancouver, BC V6C 2T7

1040433 B.C. Ltd. (“**1040433**”)
804-750 West Pender Street
Vancouver, BC V6C 2T7

1040436 B.C. Ltd. (“**1040436**”)
804-750 West Pender Street
Vancouver, BC V6C 2T7

1040440 B.C. Ltd. (“**1040440**”)
804-750 West Pender Street
Vancouver, BC V6C 2T7

Genix Pharmaceuticals Corp. (formerly 1040442 B.C. Ltd.) (“**Genix**”)
804-750 West Pender Street
Vancouver, BC V6C 2T7

(collectively, the “**Parties**”).

Item 2: Description of the Transaction

The Parties are pleased to announce that on October 29, 2015 (the “**Effective Date**”), they completed a statutory arrangement under a plan of arrangement (the “**Arrangement**”). As a result of completing the Arrangement, 1040426, 1040428, 1040433, 1040436, 1040440 and Genix became reporting issuers in the provinces of British Columbia and Alberta.

Completion of the Arrangement as set forth in the arrangement agreement and plan of arrangement dated July 20, 2015 (the “**Arrangement Agreement**”) among the Parties was approved by the shareholders of Kidani on August 14, 2015, and by a Final Order granted by the Supreme Court of British Columbia on August 19, 2015, in accordance with Part 9 of the *Business Corporations Act* (British Columbia).

Item 3: Effective Date of the Transaction

October 29, 2015.

Item 4: Names of each party, if any, that ceased to be a reporting issuer subsequent to the transaction and name of the continuing entities

No party ceased to be a reporting issuer subsequent to the completion of the Arrangement.

Upon completion of the Arrangement, Kidani continued to be a reporting issuer in the provinces of British Columbia and Alberta and 1040426, 1040428, 1040433, 1040436, 1040440 and Genix became reporting issuers in the provinces of British Columbia and Alberta.

Item 5: The date of the reporting issuer's first financial year-end after the Arrangement

July 31, 2016.

Item 6: The periods, including the comparative periods, if any, of the interim and annual Financial statements required to be filed for the reporting issuers' first financial year after the Arrangement Financial Statement Period Filing Due Date Comparatives

Financial Statement Period	Filing Due Date	Comparatives
Interim financial statements for the first quarter ended October 31, 2015.	December 30, 2015	N/A
Interim financial statements for the second quarter ended January 31, 2016.	March 31, 2016	N/A
Interim financial statements for the third quarter ended April 30, 2016.	June 29, 2016	N/A
Annual financial statements for the year ended July 31, 2016.	November 28, 2016	N/A

Item 7: Documents filed under National Instrument 51-102 that describe the Arrangement and where those documents can be found in electronic format

Please refer to (i) the information circular of Kidani dated July 20, 2015 which was filed on SEDAR under Kidani's profile at www.sedar.com on July 23, 2015, and (ii) the Arrangement Agreement, which is attached as Schedule "B" to the information circular.

DATED at Vancouver, British Columbia, as of this 30th day of October, 2015.

GENIX PHARMACEUTICALS CORP.

Christopher P. Cherry
President, CEO & CFO